Список литературы

Поставить закладку

Sanz M.A. et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. // Blood. 2009. Vol. 113, № 9. P. 1875–1891.
Савченко В.Г., Паровичникова Е.Н. Острый промиелоцитарный лейкоз. М.: Литерра, 2010. 200 p.
Acute Myeloid Leukemia. National Comprehensive Cancer Network (NCCN) Guidelines. 2-2020. [Electronic resource]. URL: https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf.
Паровичникова Е.Н., Соколов А.Н., Савченко В.Г. Протокол лечения острого промиелоцитарного лейкоза AIDA // Программное лечение заболеваний крови, под ред. Савченко В.Г. 2012. P. 265–287.
Tallman M.S., Altman J.K. How I treat acute promyelocytic leukemia // Blood. 2009. Vol. 114, № 25. P. 5126–5135.
Brain B.J. Acute promyelocytic leukemia // Leukemia Diagnosis / ed. Brain B.J. Blackwell Science, 1999. P. 14–19.
Bene M.C. et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). // Leukemia. 1995. Vol. 9, № 10. P. 1783–1786.
Rowley J.D., Golomb H.M., Dougherty C. 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia // The Lancet. 1977. Vol. 309, № 8010. P. 549– 550.
Fukutani H. et al. Molecular Heterogeneity of the PML Gene Rearrangement in Acute Promyelocytic Leukemia: Prevalence and Clinical Significance // Japanese J. Cancer Res. 1993. Vol. 84, № 3. P. 257–264.
Baba S.M. et al. Influence of bcr-3 PML-RARα transcript on outcome in Acute Promyelocytic Leukemia patients of Kashmir treated with all-trans retinoic acid and/or arsenic tri-oxide. // Cancer Genet. 2019. Vol. 231–232. P. 14–21.
Ku G.H. et al. Venous thromboembolism in patients with acute leukemia: Incidence, risk factors, and effect on survival // Blood. 2009. Vol. 113, № 17. P. 3911–3917.
Grimwade D. The significance of minimal residual disease in patients with t(15;17) // Best Pract. Res. Clin. Haematol. Bailliere Tindall Ltd, 2002. Vol. 15, № 1. P. 137–158.
Chendamarai E. et al. Role of minimal residual disease monitoring in acute promyelocytic leukemia treated with arsenic trioxide in frontline therapy. // Blood. 2012. Vol. 119, № 15. P. 3413–3419.
Ravandi F., Walter R.B., Freeman S.D. Evaluating measurable residual disease in acute myeloid leukemia. // Blood Adv. 2018. Vol. 2, № 11. P. 1356–1366.
Fang R.C., Aboulafia D.M. HIV infection and myelodysplastic syndrome/acute myeloid leukemia // HIV-Associated Hematological Malignancies. 2016. P. 133–144.
Rossi D. et al. Occult hepatitis B virus infection of peripheral blood mononuclear cells among treatment-naïve patients with chronic lymphocytic leukemia // Leuk. Lymphoma. 2009. Vol. 50, № 4. P. 604–611.
Freeman A.J. et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection.
Ribas A. et al. How important is hepatitis C virus (HCV)-infection in persons with acute leukemia? // Leuk. Res. 1997. Vol. 21, № 8. P. 785–788.
Leahy M.F., Mukhtar S.A. From blood transfusion to patient blood management: a new paradigm for patient care and cost assessment of blood transfusion practice. // Intern. Med. J. 2012. Vol. 42, № 3. P. 332–338.
Barbey J.T., Pezzullo J.C., Soignet S.L. Effect of arsenic trioxide on QT interval in patients with advanced malignancies // J. Clin. Oncol. 2003. Vol. 21, № 19. P. 3609–3615.
Herrmann J. et al. Evaluation and management of patients with heart disease and cancer: Cardio-oncology // Mayo Clin. Proc. 2014. Vol. 89, № 9. P. 1287–1306.
Никитин Е.А. et al. Хронический лимфолейкоз. // Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; под ред. И.В. Поддубной, В.Г. Савченко. 2018. P. 179–200.
Bodey G.P., Kontoyiannis D., Keating M.J. Infections in Patients With Chronic Lymphocytic Leukemia // Chronic Lymphocytic Leukemia. Totowa, NJ: Humana Press, 2004. P. 343–359.
Клясова Г.А. et al. Возбудители сепсиса у иммунокомпрометированных больных: структура и проблемы антибиотикорезистентности (результаты многоцентрового исследования) // Гематология и трансфузиология. 2007. Vol. 52, № 1. P. 11–18.
Park J.H. et al. Early death rate in acute promyelocytic leukemia remains high despite all- trans retinoic acid. // Blood. 2011. Vol. 118, № 5. P. 1248–1254.
Lehmann S. et al. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. // Leukemia. 2011. Vol. 25, № 7. P. 1128–1134.
Mantha S., Tallman M.S., Soff G.A. What’s new in the pathogenesis of the coagulopathy in acute promyelocytic leukemia? // Curr. Opin. Hematol. 2016. Vol. 23, № 2. P. 121–126.
Mantha S. et al. Determinants of fatal bleeding during induction therapy for acute
Meijer K. et al. Successful treatment of massive hemoptysis in acute leukemia with recombinant factor VIIa. // Arch. Intern. Med. 2000. Vol. 160, № 14. P. 2216–2217.
Pemmaraju N. et al. Successful Treatment of Intracranial Hemorrhage with Recombinant Activated Factor VII in a Patient with Newly Diagnosed Acute Myeloid Leukemia: A Case Report and Review of the Literature. // Front. Oncol. 2015. Vol. 5. P. 29.
Li X. et al. Combined chemotherapy for acute promyelocytic leukemia: a meta-analysis // Hematology. Taylor and Francis Ltd., 2017. Vol. 22, № 8. P. 450–459.
Fenaux P. et al. Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL group. // Leukemia. 2000. Vol. 14, № 8. P. 1371– 1377.
Fenaux P. et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. // Blood. 1999. Vol. 94, № 4. P. 1192–1200.
Shen Z.-X. et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. // Proc. Natl. Acad. Sci. U. S. A. 2004. Vol. 101, № 15. P. 5328–5335.
Powell B.L. et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. // Blood. 2010. Vol. 116, № 19. P. 3751–3757.
Iland H.J. et al. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: A non-randomised phase 2 trial // Lancet Haematol. 2015. Vol. 2,
Lo-Coco F. et al. Retinoic Acid and Arsenic Trioxide for APL // N. Engl. J. Med. 2013. Vol. 369, № 2. P. 111–121.
Platzbecker U. et al. Improved Outcomes With ATRA and ATO compared with ATRA and Chemo in non-high-risk APL_Final Results of APL0406 trial // J. Clin. Oncol. American Society of Clinical Oncology, 2017. Vol. 35, № 6. P. 605–612.
Sanz M.A., Montesinos P. How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia. // Blood. 2014. Vol. 123, № 18. P. 2777–2782.
Lo-Coco F., Cicconi L., Breccia M. Current standard treatment of adult acute promyelocytic leukaemia. // Br. J. Haematol. 2016. Vol. 172, № 6. P. 841–854.
Lo-Coco F. et al. Front-line treatment of acute promyelocytic leukemia with AIDA
Sanz M.A. et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. // Blood. 2000. Vol. 96, № 4. P. 1247–1253.
Tallman M.S. et al. All-trans retinoic acid in acute promyelocytic leukemia: Long-term outcome and prognostic factor analysis from the North American Intergroup protocol // Blood. 2002. Vol. 100, № 13. P. 4298–4302.
Montesinos P. et al. Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis. // Haematologica. 2009. Vol. 94, № 9. P. 1242–1249.
Finsinger P. et al. Acute promyelocytic leukemia in patients aged >70 years: the cure beyond the age. // Ann. Hematol. 2015. Vol. 94, № 2. P. 195–200.
Chang A., Patel S. Treatment of Acute Myeloid Leukemia During Pregnancy // Annals of Pharmacotherapy. 2015. Vol. 49, № 1. P. 48–68.
Троицкая В.В. et al. Лечение острого промиелоцитарного лейкоза на фоне беременности // Терапевтический архив. 2013. Vol. 10. P. 56–63.
Browne H., Mason G., Tang T. Retinoids and pregnancy: an update // Obstet. Gynaecol. 2014. Vol. 16. P. 7–11.
Arsenic trioxide Pregnancy and Breastfeeding Warnings [Electronic resource]. 2018. URL: https://www.drugs.com/pregnancy/arsenic-trioxide.html#ref_pregnancy.
Salem M.N., Abbas A.M., Ashry M. Dexamethasone for the prevention of neonatal respiratory morbidity before elective cesarean section at term // Proc. Obstet. Gynecol. 2016. Vol. 6, № 3. P. 1–10.
Gill H. et al. Long-term outcome of relapsed acute promyelocytic leukemia treated with oral arsenic trioxide-based reinduction and maintenance regimens: A 15-year prospective study. // Cancer. 2018. Vol. 124, № 11. P. 2316–2326.
Lengfelder E. et al. Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet // Leukemia. 2015. Vol. 29, № 5. P. 1084–1091.
Ganzel C. et al. Autologous transplant remains the preferred therapy for relapsed APL in CR2 // Bone Marrow Transplant. Nature Publishing Group, 2016. Vol. 51, № 9. P. 1180– 1183.
Ramadan S.M. et al. Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia in the ATRA and ATO era // Haematologica. 2012. Vol. 97, № 11. P. 1731–1735.
Furuya A. et al. Central nervous system involvement of acute promyelocytic leukemia, three case reports // Clin. Case Reports. Wiley, 2017. Vol. 5, № 5. P. 645–653.
López-Jiménez J. et al. Chemotherapy-induced nausea and vomiting in acute leukemia and stem cell transplant patients: results of a multicenter, observational study. // Haematologica. 2006. Vol. 91, № 1. P. 84–91.
Enno A. et al. Co-trimoxazole for prevention of infection in acute leukaemia. // Lancet (London, England). 1978. Vol. 2, № 8086. P. 395–397.
Абузарова Г.Р. et al. Обезболивание взрослых и детей при оказании медицинской помощи. Методические рекомендации. ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России., 2016. 94 p.
Paul K.L. Rehabilitation and exercise considerations in hematologic malignancies. // Am.
Охмат В.А. et al. Спектр и этиология инфекционных осложнений у больных острыми миелоидными лейкозами на этапах индукции и консолидации ремиссии // Гематология и трансфузиология. 2017. Vol. 62, № 1. P. 9–15.
Охмат В.А. et al. Инфекционные осложнения у взрослых больных острыми лимфобластными лейкозами на разных этапах химиотерапии по протоколу ОЛЛ- 2009. // Онкогематология. 2017. Vol. 12, № 3. P. 31–40.
Клясова Г.А., Охмат В.А. Антимикробная терапия // Алгоритмы диагностики и протоколы лечения заболеваний системы крови. Под редакцией Савченко В.Г. Москва: Практика, 2018. P. 1067–1114.
Maertens J. et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: Summary of the ECIL 32009 update // Bone Marrow Transplant. Nature Publishing Group, 2011. Vol. 46, № 5. P. 709–718.
Kollef M.H. et al. Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial // Lancet Infect. Dis. Lancet Publishing Group, 2019. Vol. 19, № 12. P. 1299–1311.
Averbuch D. et al. Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: Guidelines of the 4th European conference on Infections in Leukemia (ECIL-4, 2011) // Haematologica. Ferrata Storti Foundation, 2013. Vol. 98, № 12. P. 1836–1847.
Debast S.B. et al. European society of clinical microbiology and infectious diseases: Update of the treatment guidance document for Clostridium difficile infection // Clin. Microbiol.
Styczynski J. et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: Guidelines from the Second European Conference on Infections in Leukemia // Bone Marrow Transplant. Bone Marrow Transplant, 2009. Vol. 43, № 10. P. 757–770.
Ljungman P. et al. Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT // Bone Marrow Transplant. Bone Marrow Transplant, 2008. Vol. 42, № 4. P. 227–240.
Arendrup M.C. et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections // Clin. Microbiol. Infect. Blackwell Publishing Ltd, 2014. Vol. 20, № S3. P. 76–98.
Tissot F. et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients // Haematologica. Ferrata Storti Foundation, 2017. Vol. 102, № 3. P. 433–444.
Мальчикова А.О., Клясова Г.А. Формирование биопленок у изолятов Candida spp, выделенных из гемокультуры от больных с опухолями системы крови // Клиническая микробиология и антимикробная химиотерапия. 2018. Vol. 20, № 2. P. 126–130.
Ullmann A.J. et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline // Clin. Microbiol. Infect. Elsevier B.V., 2018. Vol. 24. P. e1–e38.
Cornely O.A. et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium // The Lancet Infectious Diseases. Lancet Publishing Group, 2019. Vol. 19, № 12. P. e405–e421.
Tortorano A.M. et al. ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others // Clin. Microbiol. Infect. Blackwell Publishing Ltd, 2014. Vol. 20, № S3. P. 27–46.
Maschmeyer G. et al. ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients // J. Antimicrob. Chemother. J Antimicrob Chemother, 2016. Vol. 71, № 9. P. 2405–2413.
Maertens J. et al. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients // Journal of Antimicrobial Chemotherapy. Oxford University Press, 2016. Vol. 71, № 9. P. 1–8.
Singer M. et al. The third international consensus definitions for sepsis and septic shock (sepsis-3) // JAMA - Journal of the American Medical Association. American Medical
Мамонов В.Е. Неотложная нейрохирургия внутричерепных кровоизлияний у пациентов гематологического стационара // Гематология и трансфузиология. 2020. Vol. 65, № S1. P. 174–175.
Пантелеев М.А. et al. Практическая коагулология. 2010. 192 p.
Hayward C.P.M. How I investigate for bleeding disorders // International Journal of Laboratory Hematology. Blackwell Publishing Ltd, 2018. Vol. 40. P. 6–14.
Falanga A., Rickles F.R. Management of Thrombohemorrhagic Syndromes (THS) in hematologic malignancies. // Hematology Am. Soc. Hematol. Educ. Program. Hematology Am Soc Hematol Educ Program, 2007. P. 165–171.
Чернуха Г.Е. Аномальные маточные кровотечения репродуктивного периода // Гинекология: национальное руководство. Краткое издание. Под ред. Г.М. Савельевой. Г.Т. Сухих, В.Н. Серова, В.Е. Радзинского, И.Б. Манухина. М.: ГЭОТАР- Медиа, 2020. P. 170–175.
Доброхотова Ю.Э. et al. Аномальные маточные кровотечения: алгоритмы ведения, методы терапии // РМЖ. Мать и дитя. 2020. Vol. 3, № 1. P. 55–60.
Annibali O. et al. Incidence of venous thromboembolism and use of anticoagulation in hematological malignancies: Critical review of the literature // Critical Reviews in Oncology/Hematology. Elsevier Ireland Ltd, 2018. Vol. 124. P. 41–50.
Falanga A., Marchetti M., Russo L. Venous thromboembolism in the hematologic malignancies // Current Opinion in Oncology. Curr Opin Oncol, 2012. Vol. 24, № 6. P. 702–710.
Воробьев А.И. et al. Гиперкоагуляционный синдром: классификация, патогенез, диагностика, терапия // Гематология и трансфузиология. 2016. Vol. 61, № 3. P. 116– 122.
Greenberg C.S. The role of D-dimer testing in clinical hematology and oncology // Clin. Adv. Hematol. Oncol. 2017. Vol. 15, № 8. P. 580–583.
Weitz I.C. et al. Chemotherapy-induced activation of hemostasis: effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activation // Thromb. Haemost. 2002. Vol. 88, № 2. P. 213–220.
Sharifi M. et al. New oral anticoagulants in the treatment of heparin- Induced thrombocytopenia // Thromb. Res. Elsevier Ltd, 2015. Vol. 135, № 4. P. 607–609.
Абузарова Г.Р. Лечение болевого синдрома у онкологических больных // Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; под ред. И.В. Поддубной, В.Г. Савченко. 2018.
Когония Л.М. et al. Практические рекомендации по лечению хронического болевого синдрома у онкологических больных. // Злокачественные опухоли: Практические рекомендации RUSSCO. 2018. P. 617–635.
Fallon M. et al. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. // Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2018. Vol. 29, № Suppl 4. P. iv166–iv191.
Авыдов О.С. et al. Невропатическая боль: клинические рекомендации по диагностике и лечению Российского общества по изучению боли // Российский журнал боли. 2018. Vol. 4. P. 5–40.
Гендлин Г.Е. et al. Современный взгляд на кардиотоксичность химиотерапии онкологических заболеваний, включающей антрациклиновые антибиотики. // Российский кардиологический журнал. 2017. Vol. 143, № 3. P. 145–154.
Васюк Ю.А. et al. Возможности современных эхокардиографических технологий в ранней диагностике кардиотоксического действия химиотерапевтических препаратов антрациклинового ряда у онкологических больных. // Кардиология. 2017. Vol. 57, № S4. P. 31–17.
Zamorano J.L. et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines // European Heart Journal. Oxford University Press, 2016. Vol. 37, № 36. P. 2768–2801.
Larsen C.M., Mulvagh S.L. Cardio-oncology: What you need to know now for clinical practice and echocardiography // Echo Research and Practice. BioScientifica Ltd., 2017. Vol. 4, № 1. P. R33–R41.
Титова В.Б., Беляева Н.М. Вирусный гепатит В у иммуносупрессивных пациентов с онкологическими заболеваниями: патогенез, ведение и профилактика // Инфекционные болезни. 2014. Vol. 12, № 3. P. 51–60.
Papatheodoridis G. et al. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection // Journal of Hepatology. Elsevier B.V., 2012. Vol. 57, № 1. P. 167–185.
Coppola N. et al. Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings // J. Med. Virol. J Med Virol, 2011. Vol. 83, № 11. P. 1909– 1916.
Sanchez M.J. et al. Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab q // J. Hepatol. Vol. 51. P. 1091– 1096.
Liang R. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation // Blood. American Society of Hematology, 2009. Vol. 113, № 14. P. 3147–3153.
Firpi R.J., Nelson D.R. Management of viral hepatitis in hematologic malignancies // Blood Rev. 2008. Vol. 22, № 3. P. 117–126.
Ennishi D. et al. Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV- infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy
Roche B., Samuel D. The difficulties of managing severe hepatitis B virus reactivation // Liver Int. Liver Int, 2011. Vol. 31, № SUPPL. 1. P. 104–110.
Baumeister M.A. et al. Hepatitis B virus e antigen specific epitopes and limitations of commercial anti-HBe immunoassays // J. Med. Virol. John Wiley & Sons, Ltd, 2000. Vol. 60, № 3. P. 256–263.
Torres H.A., Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer // Nature Reviews Clinical Oncology. Nat Rev Clin Oncol, 2012. Vol. 9, № 3. P. 156–166.
Rupp D., Bartenschlager R. Targets for antiviral therapy of hepatitis C // Semin. Liver Dis. Thieme Medical Publishers, Inc., 2014. Vol. 34, № 1. P. 9–21.
Prieto J.M. et al. Psychiatric morbidity and impact on hospital length of stay among hematologic cancer patients receiving stem-cell transplantation // J. Clin. Oncol. J Clin Oncol, 2002. Vol. 20, № 7. P. 1907–1917.
Mitchell A.J. et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: A meta-analysis of 94 interview- based studies // Lancet Oncol. Lancet Oncol, 2011. Vol. 12, № 2. P. 160–174.
Howard S.C., Jones D.P., Pui C.-H. The Tumor Lysis Syndrome // N. Engl. J. Med. Massachusetts Medical Society, 2011. Vol. 364, № 19. P. 1844–1854.
Wilson F.P., Berns J.S. Tumor Lysis Syndrome: New Challenges and Recent Advances // Advances in Chronic Kidney Disease. Adv Chronic Kidney Dis, 2014. Vol. 21, № 1. P. 18– 26.
Cairo M.S. et al. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: An expert TLS panel consensus // Br. J. Haematol. Br J Haematol, 2010. Vol. 149, № 4. P. 578–586.
Pession A. et al. Risk evaluation, prophylaxis, and treatment of tumor lysis syndrome: Consensus of an italian expert panel // Adv. Ther. Adv Ther, 2011. Vol. 28, № 8. P. 684– 697.
Sarno J. Prevention and management of tumor lysis syndrome in adults with malignancy. //
Джумабаева Б.Т. et al. Клинико-лабораторные и морфологические особенности поражения почек при лимфопролиферативных заболеваниях // Онкогематология. 2017. Vol. 7, № 1. P. 44–54.
Рехтина И.Г. et al. Морфологические и иммунохимические особенности нефропатий при множественной миеломе с тяжелой почечной недостаточностью // Терапевтический архив. 2013. Vol. 85, № 3. P. 80–85.
Ворожейкина Е.Г., Бирюкова Л.С., Савченко В.Г. Клинико-лабораторные проявления нефропатий у больных острыми лейкозами // Гематология и трансфузиология. 2011. Vol. 56, № 3. P. 24–27.
Sanz M.A. et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARα-positive acute promyelocytic leukemia // Blood. 1999. Vol. 94, № 9. P. 3015–3021.
Burnett A.K. et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): Results of a randomised, controlled, phase 3 trial // Lancet Oncol. Lancet Publishing Group, 2015. Vol. 16, № 13. P. 1295–1305.
Протоколы трансплантации аллогенных гепомоэтических стволовых клеток. Под ред. В.Г. Савченко. М.: Практика, 2020. 320 p.
Welte K. et al. Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor // Proc. Natl. Acad. Sci. U. S. A. Proc Natl Acad Sci U S A, 1985. Vol. 82, № 5. P. 1526–1530.
Krause D.S. et al. CD34: Structure, biology, and clinical utility // Blood. American Society of Hematology, 1996. Vol. 87, № 1. P. 1–13.
Giralt S. et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: Consensus guidelines and recommendations // Biology of Blood and Marrow Transplantation. Elsevier, 2014. Vol. 20, № 3. P. 295–308.
Stiff P.J. et al. Transplanted CD34 + Cell Dose Is Associated with Long-Term Platelet Count Recovery following Autologous Peripheral Blood Stem Cell Transplant in Patients with Non-Hodgkin Lymphoma or Multiple Myeloma // Biol. Blood Marrow Transplant. Biol Blood Marrow Transplant, 2011. Vol. 17, № 8. P. 1146–1153.
Passos-Coelho J.L. et al. Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte- macrophage colony-stimulating factor mobilization // J. Clin. Oncol. American Society of Clinical Oncology, 1995. Vol. 13, № 3. P. 705–714.
Hohaus S. et al. Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF. // Exp. Hematol. 1993. Vol. 21, № 4. P. 508–514.
Покровская О.С., Менделеева Л.П., Гальцева И.В., Варламова Е.Ю., Капланская И.Б., Воробьев И.А., Грецов Е.М., Калинин Н.Н., Варламова С.В., Клясова Г.А., Тихонова Л.Ю. С.В.Г. Мобилизация гемопоэтических клеток крови у больных миеломной болезнью // Проблемы гематологии и переливания. 2003. P. 55–56.
Olivieri A. et al. Proposed definition of “poor mobilizer” in lymphoma and multiple myeloma: An analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo // Bone Marrow Transplant. Bone Marrow Transplant, 2012. Vol. 47, № 3. P. 342–351.
Yang B.B., Kido A. Pharmacokinetics and pharmacodynamics of pegfilgrastim // Clinical Pharmacokinetics. Clin Pharmacokinet, 2011. Vol. 50, № 5. P. 295–306.
Costa L.J. et al. Pegfilgrastim-versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: Efficacy and cost analysis // Transfusion. Transfusion, 2012. Vol. 52, № 11. P. 2375–2381.
Dale D.C. et al. A systematic literature review of the efficacy, effectiveness, and safety of filgrastim // Supportive Care in Cancer. Springer Verlag, 2018. Vol. 26, № 1. P. 7–20.
Smith T.J. et al. Recommendations for the use of WBC growth factors: American society of clinical oncology clinical practice guideline update // J. Clin. Oncol. American Society of Clinical Oncology, 2015. Vol. 33, № 28. P. 3199–3212.
Bilgin Y.M., De Greef G.E. Plerixafor for stem cell mobilization: The current status // Current Opinion in Hematology. Lippincott Williams and Wilkins, 2016. Vol. 23, № 1. P. 67–71.
Бабенецкая Д.В., Моторин Д.В., Петров А.В., Алексеева Ю.А. З.А.Ю. Мобилизация гемопоэтических стволовых клеток препаратами циклофосфамид и цитарабин в сочетании с колониестимулирующим фактором у больных множественной миеломой, кандидатов для проведения трансплантации аутологичных гемопоэтических стволовых клеток // Гематология и трансфузиология. 2017. № 62(4). P. 180-187.
Покровская О.С. Кроветворная ткань и стромальное микроокружение в процессе интенсивной терапии и мобилизации гемопоэтических стволовых клеток у больных множественной миеломой: Автореф. дис.канд.мед.наук. 2011. Vol. 153. 29 p.
Афанасьева О.И., Воинов В.А. Г.Ю.С. Экстракорпоральная гемокоррекция: терминология, языковые соответствия. СПб, 2016. P. 7–15.
Ikeda K. et al. Adverse Events Associated With Infusion of Hematopoietic Stem Cell Products: A Prospective and Multicenter Surveillance Study // Transfusion Medicine Reviews. W.B. Saunders, 2018. Vol. 32, № 3. P. 186–194.
Sutherland D.R. et al. The ISHAGE guidelines for CD34+ cell determination by flow cytometry // Journal of Hematotherapy and Stem Cell Research. J Hematother, 1996. Vol. 5, № 3. P. 213–226.
Савченко В.Г. и др. Алгоритмы диагностики и протоколы лечения заболеваний системы крови. Москва: Практика, 2018. 1008 p.
JL H.C. et al. Autologous Is Superior to Allogeneic Hematopoietic Cell Transplantation for Acute Promyelocytic Leukemia in Second Complete Remission // Biol. Blood Marrow Transplant. Biol Blood Marrow Transplant, 2014. Vol. 20, № 7.
Gondo H. et al. Autologous peripheral blood stem cell transplantation for acute myelogenous leukemia. // Bone Marrow Transplant. Bone Marrow Transplant, 1997. Vol. 20, № 10. P. 821–826.
Enric Carreras D.C., Mohty Mohamad K.N. Hematopoietic Stem Cell Transplantation and Cellular Therapies. 2019. 702 p.
Narum S., Westergren T., Klemp M. Corticosteroids and risk of gastrointestinal bleeding: A systematic review and meta-analysis // BMJ Open. BMJ Publishing Group, 2014. Vol. 4,
Conn H.O., Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. // J. Intern. Med. J Intern Med, 1994. Vol. 236, № 6. P. 619–632.
Ивашкин В.Т. et al. Диагностика и лечение язвенной болезни у взрослых (Клинические рекомендации Российской гастроэнтерологической ассоциации, Российского общества колоректальных хирургов и Российского эндоскопического общества). // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020. Vol. 30, № 1. P. 49–70.
Burget D.W., Chiverton S.G., Hunt R.H. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression // Gastroenterology. Gastroenterology, 1990. Vol. 99, № 2. P. 345–351.
Scally B. et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials // Lancet Gastroenterol. Hepatol. Elsevier Ltd, 2018. Vol. 3, № 4. P. 231–241.
Hu Z.-H. et al. Efficacy of proton pump inhibitors for patients with duodenal ulcers: A pairwise and network meta-analysis of randomized controlled trials // Saudi J. Gastroenterol. Medknow Publications, 2017. Vol. 23, № 1. P. 11.
Lanas A., Chan F.K.L. Peptic ulcer disease. // Lancet (London, England). Lancet, 2017. Vol. 390, № 10094. P. 613–624.
Auner H.W. et al. Infectious complications after autologous hematopoietic stem cell transplantation: Comparison of patients with acute myeloid leukemia, malignant lymphoma, and multiple myeloma // Ann. Hematol. Ann Hematol, 2002. Vol. 81, № 7. P. 374–377.
Gil L., Styczynski J., Komarnicki M. Infectious complication in 314 patients after high- dose therapy and autologous hematopoietic stem cell transplantation: Risk factors analysis and outcome // Infection. Infection, 2007. Vol. 35, № 6. P. 421–427.
Eleutherakis-Papaiakovou E. et al. Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem-cell transplantation: Results of a single institution, randomized phase 2 trial // Am. J. Hematol. Am J Hematol, 2010. Vol. 85, № 11. P. 863–867.
Neumann S. et al. Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DG // Annals of Hematology. Ann Hematol, 2013. Vol. 92, № 4. P. 433–442.
Moghnieh R. et al. Bacteraemia post-autologous haematopoietic stem cell transplantation in the absence of antibacterial prophylaxis: a decade’s experience from Lebanon // Infection. Urban und Vogel GmbH, 2018. Vol. 46, № 6.
Клясова Г.А. et al. Эмпирическая антимикробная терапия у больных острыми лейкозами: итоги многоцентрового исследования // Терапевтический архив. 1998. Vol. 70, № 7. P. 15–21.
Terpos E. et al. European myeloma network guidelines for the management of multiple myeloma-related complications // Haematologica. Ferrata Storti Foundation, 2015. Vol. 100, № 10. P. 1254–1266.
Сытов А.В., Лейдерман И.Н., Ломидзе С.В., Нехаев И.В. Х.А.Ж.. Практические рекомендации по нутритивной поддержке онкологических больных // RUSSCO. 2017. P. 524–532.
Virizuela J.A. et al. Nutritional support and parenteral nutrition in cancer patients: an expert consensus report // Clin. Transl. Oncol. Springer-Verlag Italia s.r.l., 2018. Vol. 20, № 5. P. 619–629.
Бесова Н.С., Борисова Т.Н., Ларионова В.Б., Лейдерман И.Н., Обухова О.А., Попова Т.С., Салтанов А.И., Сельчук В.Ю., Снеговой А.В., Ткачев С.И., Тюляндин С.А. Ш.А.И. Клинические рекомендации по нутритивной поддержке при химиотерапии
Arends J. et al. ESPEN guidelines on nutrition in cancer patients // Clin. Nutr. Churchill Livingstone, 2017. Vol. 36, № 1. P. 11–48.
Camblor-Álvarez M. et al. Soporte nutricional y nutrición parenteral en el paciente oncológico: informe de consenso de un grupo de expertos // Nutr. Hosp. ARAN Ediciones, 2018. Vol. 35, № 1.
Baiu I., Spain D.A. Parenteral Nutrition // JAMA - Journal of the American Medical Association. American Medical Association, 2019. Vol. 321, № 21. P. 2142.
SPIRIN M., GALSTYAN G., DROKOV M. Central venous access in lymphoma patients (pts) with superior vena cava syndrome (SVCS) // INTENSIVE CARE Med. Exp. 2019. Vol. 7, № Suppl. 3:001341. P. 388–389.
Pluschnig U. et al. Extravasation emergencies: state-of-the-art management and progress in clinical research. // Memo. Springer, 2016. Vol. 9, № 4. P. 226–230.
Zeidler K. et al. Optimal preprocedural platelet transfusion threshold for central venous catheter insertions in patients with thrombocytopenia. // Transfusion. 2011. Vol. 51, № 11. P. 2269–2276.
Zerati A.E. et al. Totally implantable venous catheters : history , implantation technique and complications. // J Vasc Bras. 2017. Vol. 16, № 2. P. 128–139.
Gow K.W., Tapper D., Hickman R.O. Between the lines: The 50th anniversary of long-term central venous catheters // Am. J. Surg. Elsevier Ltd, 2017. Vol. 213, № 5. P. 837–848.
Yeral M. et al. Tunnelled central venous catheter-related problems in the early phase of haematopoietic stem cell transplantation and effects on transplant outcome. // Turkish J. Haematol. Off. J. Turkish Soc. Haematol. Galenos Yayinevi, 2015. Vol. 32, № 1. P. 51– 57.
Maki D.G., Kluger D.M., Crnich C.J. The Risk of Bloodstream Infection in Adults With Different Intravascular Devices: A Systematic Review of 200 Published Prospective Studies
Hamilton H. Central Venous Catheters / ed. Bodenham A.R. Oxford, UK: Wiley-Blackwell, 2009.
Biffi R. Introduction and Overview of PICC History // Peripherally Inserted Central Venous Catheters. Milano: Springer Milan, 2014. P. 1–6.
Linenberger M.L. Catheter-related thrombosis: risks, diagnosis, and management. // J. Natl. Compr. Canc. Netw. 2006. Vol. 4, № 9. P. 889–901.
Lee A.Y.Y., Kamphuisen P.W. Epidemiology and prevention of catheter-related thrombosis in patients with cancer // J. Thromb. Haemost. 2012. № 10. P. 1491–1499.
Цепенщинков Л.., Лядов В.К. Периферически имплантируемый центральный венозный катетер: обзор литераутры. // Клиническая онкогематология. 2014. Vol. 7,
Linder L.E. et al. Material thrombogenicity in central venous catheterization: a comparison between soft, antebrachial catheters of silicone elastomer and polyurethane. // JPEN. J. Parenter. Enteral Nutr. 1984. Vol. 8, № 4. P. 399–406.
Watters V.A., Grant J.P. Use of Electrocardiogram to Position Right Atrial Catheters During Surgery // Ann. Surg. Vol. 225, № 2. P. 165–171.
Taal M.W., Chesterton L.J., McIntyre C.W. Venography at insertion of tunnelled internal jugular vein dialysis catheters reveals significant occult stenosis // Nephrol. Dial. Transplant. Oxford University Press, 2004. Vol. 19, № 6. P. 1542–1545.
Lobato E.B. et al. Cross-sectional area of the right and left internal jugular veins. // J. Cardiothorac. Vasc. Anesth. 1999. Vol. 13, № 2. P. 136–138.
Червонцева А.М. Повреждение сосудистого эндотелия в процессе лечения острых миелоидных лейкозов. 2008.
Багирова Н.С. Инфекции, связанные с внутрисосудистыми устройствами: терминология, диагностика, профилактика и терапия // Злокачественные опухоли. 2014. № 3. P. 164–171.
Bannon M.P., Heller S.F., Rivera M. Anatomic considerations for central venous cannulation. // Risk Manag. Healthc. Policy. Dove Press, 2011. Vol. 4. P. 27–39.
Milling T.J. et al. Randomized, controlled clinical trial of point-of-care limited ultrasonography assistance of central venous cannulation: The Third Sonography Outcomes Assessment Program (SOAP-3) Trial* // Crit. Care Med. 2005. Vol. 33, № 8. P. 1764–1769.
Зозуля Н.И., Кумскова М.А. Протокол диагностики и лечения гемофилии. // Алгоритмы диагностики и протоколы лечения заболеваний системы крови. Том 1. Практика / ed. Савченко В.Г. Москва, 2018. P. 333–358.
Галстян Г.М. НАРУШЕНИЯ ГЕМОСТАЗА, ОБУСЛОВЛЕННЫЕ ДЕФИЦИТОМ ВИТАМИН К-ЗАВИСИМЫХ ФАКТОРОВ СВЕРТЫВАНИЯ КРОВИ — ПАТОГЕНЕЗ, СПОСОБЫ КОРРЕКЦИИ И РЕКОМЕНДАЦИИ ПО ЛЕЧЕНИЮ. // Гематология и трансфузиология. 2012. Vol. 27, № 2. P. 7–21.
Fong B., Van Bendegon J.M. Lumbar puncture. Neurologic and neurosurgical procedures
Navari R.M., Aapro M. Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting // N. Engl. J. Med. New England Journal of Medicine (NEJM/MMS), 2016. Vol.
Ettinger D.S. et al. Antiemesis. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Version 1.2021. 2020.
Roila F. et al. Prevention of chemotherapy- and radiotherapy-induced emesis: Results of the 2004 Perugia International Antiemetic Consensus Conference // Annals of Oncology. Ann Oncol, 2006. Vol. 17, № 1. P. 20–28.
Basch E. et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update // J. Clin. Oncol. J Clin Oncol, 2011. Vol. 29, № 31. P. 4189–4198.
Hesketh P.J. et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update // Journal of Clinical Oncology. American Society of Clinical Oncology, 2017. Vol. 35, № 28. P. 3240–3261.
Razvi Y. et al. ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients // Supportive Care in Cancer. Springer Verlag, 2019. Vol. 27, № 1. P. 87–95.
Владимирова Л.Ю. et al. Практические рекомендации по профилактике и лечению тошноты и рвоты у онкологических больных // Практические рекомендации Российского общества клинической онкологии. Лекарственное лечение злокачественных опухолей. Поддерживающая терапия в онкологии. 2018. P. 502–511.
Young P. et al. Effect of a buffered crystalloid solution vs saline on acute kidney injury among patients in the intensive care unit: The SPLIT randomized clinical trial // JAMA - J. Am. Med. Assoc. American Medical Association, 2015. Vol. 314, № 16. P. 1701–1710.
Hoorn E.J. Intravenous fluids: balancing solutions // Journal of Nephrology. Springer New York LLC, 2017. Vol. 30, № 4. P. 485–492.
Криволапов Ю.А. Технические аспекты выполнения трепанобиопсий костного мозга. Клиническая онкогематология 2014; 7:290—295 // Клиническая онкогематология. 2014. Vol. 7. P. 290–295.
Wang J. et al. Diagnostic utility of bilateral bone marrow examination: Significance of morphologic and ancillary technique study in malignancy // Cancer. Cancer, 2002. Vol. 94,
Троицкая В.В. et al. Протокол индукционной фазы лечения острых лейкозов, протекающих с гиперлейкоцитозом // Алгоритмы диагностики и протоколы лечения заболеваний системы крови. НМИЦ Гематологии. Под ред. В.Г. Савченко. Практика, 2018. P. 731–752.
Porcu P. et al. Leukocytoreduction for acute leukemia // Ther. Apher. Ther Apher, 2002. Vol. 6, № 1. P. 15–23.
Szczepiorkowski Z.M. et al. Guidelines on the use of therapeutic apheresis in clinical practice - Evidence-based approach from the apheresis applications committee of the American Society for Apheresis // Journal of Clinical Apheresis. Wiley-Liss Inc., 2010. Vol. 25, № 3. P. 83–177.
Ganzel C. et al. Hyperleukocytosis, leukostasis and leukapheresis: Practice management // Blood Rev. Blood Rev, 2012. Vol. 26, № 3. P. 117–122.
Roze des Ordons A.L. et al. Clinical characteristics and outcomes of patients with acute myelogenous leukemia admitted to intensive care: A case-control study // BMC Cancer. 2010. Vol. 10. P. 516.
Schellongowski P. et al. Prognostic factors for intensive care unit admission, intensive care outcome, and post-intensive care survival in patients with de novo acute myeloid leukemia: a single center experience // Haematologica. 2011. Vol. 96, № 2. P. 231–237.
Lengliné E. et al. Intensive care unit management of patients with newly diagnosed acute myeloid leukemia with no organ failure // Leuk. Lymphoma. Leuk Lymphoma, 2012. Vol. 53, № 7. P. 1352–1359.
Jackson K. et al. Outcomes and prognostic factors for patients with acute myeloid leukemia admitted to the intensive care unit // Leuk. Lymphoma. Leuk Lymphoma, 2013. Vol. 55, № April. P. 1–8.
Pohlen M. et al. Patients with acute myeloid leukemia admitted to intensive care units: Outcome analysis and risk prediction // PLoS One. Public Library of Science, 2016. Vol. 11, № 8.
Halpern A.B. et al. Association of risk factors, mortality, and care costs of adults with acute myeloid leukemia with admission to the intensive care unit // JAMA Oncol. American Medical Association, 2017. Vol. 3, № 3. P. 374–381.
Воробьев А.И. et al. Критические состояния при гемобластозах (типичные формы и выживаемость в условиях отделения реанимации). // Терапевтический архив. 1993. Vol. 65, № 7. P. 3–6.
Галстян Г.М., Городецкий В.М. Опыт работы отделения реанимации и интенсивной терапии ФГБУ ГНЦ МЗиСР РФ // Клиническая онкогематология. 2011. Vol. 4, № 1. P. 75–78.
Lamia B. et al. Changes in severity and organ failure scores as prognostic factors in onco- hematological malignancy patients admitted to the ICU // Intensive Care Med. Intensive Care Med, 2006. Vol. 32, № 10. P. 1560–1568.
Evison J.M. et al. Intensive care unit admission in patients with haematological disease: incidence, outcome and prognostic factors. 2001.
Silfvast T. et al. Multiple organ failure and outcome of critically ill patients with haematological malignancy // Acta Anaesthesiol. Scand. Acta Anaesthesiol Scand, 2003. Vol. 47, № 3. P. 301–306.
Benoit D.D. et al. Outcome and early prognostic indicators in patients with a hematologic malignancy admitted to the intensive care unit for a life-threatening complication // Crit. Care Med. Crit Care Med, 2003. Vol. 31, № 1. P. 104–112.
Medić M.G. et al. Hematologic malignancies in the medical intensive care unit – Outcomes and prognostic factors // Hematology. Maney Publishing, 2015. Vol. 20, № 5. P. 247–253.
Ahmed T. et al. Outcomes and changes in code status of patients with acute myeloid leukemia undergoing induction chemotherapy who were transferred to the intensive care unit // Leuk. Res. Elsevier Ltd, 2017. Vol. 62. P. 51–55.
Wohlfarth P. et al. Prognostic factors, long-term survival, and outcome of cancer patients receiving chemotherapy in the intensive care unit // Ann. Hematol. Springer Verlag, 2014. Vol. 93, № 10. P. 1629–1636.
Fan E., Brodie D., Slutsky A.S. Acute Respiratory Distress Syndrome // JAMA. American Medical Association, 2018. Vol. 319, № 7. P. 698.
Gratwohl A. The EBMT risk score // Bone Marrow Transplantation. Nature Publishing Group, 2012. Vol. 47, № 6. P. 749–756.
Sorror M.L. et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. // Blood. The American Society of Hematology, 2005. Vol. 106, № 8. P. 2912–2919.
Sorror M.L. et al. Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study // Biol. Blood Marrow Transplant. Elsevier Inc., 2015. Vol. 21